Molecular docking and synthesis of novel quinazoline analogues as inhibitors of transcription factors NF-κB activation and their anti-cancer activities

Bioorganic and Medicinal Chemistry

Volumn 21, Issue 2, 2013, Pages 540-546

  Xu, Lu ^a   Russu, Wade A ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

Apoptosis; NF B cancer; Quinazoline

Indexed keywords

2 [[4 (2 PHENYLQUINAZOLIN 4 YL)PIPERAZIN 1 YL]METHYL]PHENOL; 2 [[4 (QUINAZOLIN 4 YL)PIPERAZIN 1 YL]METHYL]PHENOL; 4 (4 BENZYLPIPERAZIN 1 YL) 2 PHENYLQUINAZOLINE; 4 (4 BENZYLPIPERAZIN 1 YL)QUINAZOLINE; 4 [[4 (2 PHENYLQUINAZOLIN 4 YL)PIPERAZIN 1 YL]METHYL]PHENOL; 4 [[4 (QUINAZOLIN 4 YL)PIPERAZIN 1 YL]METHYL]PHENOL; 4 BROMO 2 [[4 (2 PHENYLQUINAZOLIN 4 YL)PIPERAZIN 1 YL]METHYL]PHENOL; 4 BROMO 2 [[4 (QUINAZOLIN 4 YL)PIPERAZIN 1 YL]METHYL]PHENOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N [2 (1H INDOL 3 YL)ETHYL]QUINAZOLIN 4 AMINE; N [2 (BENZO[D][1,3]DIOXOL 5 YL)ETHYL] 2 PHENYLQUINAZOLIN 4 AMINE; N [2 (BENZO[D][1,3]DIOXOL 5 YL)ETHYL]QUINAZOLIN 4 AMINE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOLECULAR DOCKING; PHARMACOPHORE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BENZODIOXOLES; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HCT116 CELLS; HEP G2 CELLS; HUMANS; MOLECULAR DOCKING SIMULATION; NF-KAPPA B P50 SUBUNIT; PROTEIN STRUCTURE, TERTIARY; QUINAZOLINES; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 84871630559     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2012.10.051     Document Type: Article

References (18)

1. M. Karin, Y. Yamamoto, and Q.M. Wang Nat. Rev. Drug Disc. 3 2004 17
2. M. Karin, and A. Lin Nat. Immunol. 3 2002 221
3. Y. Pommier, O. Sordet, S. Antony, R.L. Hayward, and K.W. Kohn Oncogene 23 2004 2934
4. M. Kieran, V. Blank, F. Logeat, J. Vandekerckhove, F. Lottspeich, O. Le Bail, M. Urban, P. Kourilsky, P. Baeuerle, and A. Israel Cell 1007 1990 62
5. P. Baeuerle, and D. Baltimore Genes Dev. 3 1989 1689
6. D.J. Van Antwerp, S.J. Martin, T. Kafri, D.R. Green, and I.M. Verma Science 274 1996 787
7. P. Baeuerle, and D. Baltimore Science 242 1988 540
8. Y. Yamamoto, and R.B. Gaynor J. Clin. Invest. 107 2001 135
9. Y. Kobayashi, A. Yoshimori, K. Kino, H. Miyazawa, and S.-i. Tanuma Bioorg. Med. Chem. 17 2009 5293
10. V. Pande, R.K. Sharma, J.-I. Inoue, M. Otsuka, and M.J. Ramos J. Comput. Aided Mol. Des. 17 2003 825
11. M. Tobe, Y. Isobe, H. Tomizawa, T. Nagasaki, H. Takahashi, T. Fukazawa, and H. Hayashi Bioorg. Med. Chem. 11 2003 383
12. L. Qian, Y. Shen, J.-C. Chen, Y.-X. Wang, X.-T. Wu, T.-J. Chen, and K.-C. Zheng QSAR Comb. Sci. 27 2008 984
13. K.-C. Tsai, L.-W. Teng, Y.-M. Shao, Y.-C. Chen, Y.-C. Lee, M. Li, and N.-W. Hsiao Bioorg. Med. Chem. Lett. 19 2009 5665
14. R. Van Horssen, T.L.M. Ten Hagen, and A.M.M. Eggermont Oncologist 11 2006 397
15. N. Matsumoto, A. Ariga, S. To-e, H. Nakamura, N. Agata, S.-i. Hirano, J.-i. Inoue, and K. Umezawa Bioorg. Med. Chem. Lett. 10 2000 865
16. Obtained from Cayman Chemical Company, Ann Arbor, MI, USA.
17. M. Monga, and E.A. Sausville Leukemia 16 2002 520
18. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, and M.R. Boyd J. Natl. Cancer Inst. 82 1990 1107